Zilya A. Kalmykova

Zilya A. Kalmykova

Auto-generated profile, based on publicly available information

Zilya A. Kalmykova

Endocrinology Research Centre

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMarina Shestakova
Marina Shestakova
IKIrina Kononenko
Irina Kononenko
ZKZilya Kalmykovа
Zilya Kalmykovа
TMTatyana Markova
Tatyana Markova
EKElena Kaplun
Elena Kaplun
NMNatalya Mokrysheva
Natalya Mokrysheva
Introduction: One of the stages of reproduction of SARS-CoV-2 is the S-protein glycosylation to facilitate penetration into target cells. It has been suggested that SARS-CoV-2 is able to enter erythrocytes, interact with heme and porphyrin, which could influence HbA1c levels. Assessment of HbA1c levels in individuals with acute COVID-19 and after recovery may show clinical relevance of this hypothesis. Aim: To assess HbA1c levels in patients with COVID-19 in the acute phase and in early (6–8 weeks) and late (52±2 weeks) periods after recovery. Materials and methods: We conducted a multicenter prospective study, which included patients hospitalized in Endocrinology Research Centre and the City Clinical Hospital № 52" diagnosed with COVID-19, virus identified/ not identified. Patients were divided into three groups according to baseline HbA1c level and the presence or absence of previous history of diabetes previous history of diabetes mellitus (DM): HbA1c ≤ 6.0%, HbA1c > 6.0% and patients with DM. Patients were examined during the acute COVID-19 phase and in early (6–8 weeks) and late (52±2 weeks) periods after recovery. Oral glucose tolerance test was performed in the group with initial HbA1c > 6.0% to clarify the diagnosis. Results: We included 194 patients in the study. During the follow-up, 52 patients were examined in 6–8 week period: 7 with HbA1c ≤ 6.0%, 34 with HbA1c > 6.0%, 11—with previously diagnosed DM. Carbohydrate metabolism assessment in the later stages (52±2 weeks) after recovery was performed in 78 patients: 33 patients with HbA1c ≤ 6.0%, 36 patients with HbA1c > 6.0% and 9 patients with previously established diabetes. HbA1c median in patients with HbA1c ≤ 6.0% was 5.7% [5.3;5.8], with HbA1c>6.0% -6.4% [6.2; 6.6], with previously diagnosed DM—7.7% [7.2; 8.9]. Statistically significant decrease in HbA1c over time 6–8 weeks after extracts were obtained in both groups of individuals without a history of DM (Wilcoxon test, p<0.05). After 52±2 weeks we observed HbA1c decrease in all three groups (Fridman test, p6.0% - 6.1[6.15;6.54], with previously diagnosed DM—7.8 [5.83; 8.08]. Development of DM after 52±2 weeks was recorded in 7.24% of all examined patients without a history of DM, which is 16.6% of the total number of patients examined in dynamics with HbA1c > 6.0%. Conclusion: HbA1c elevation during the acute phase of COVID-19 may be false due to the effect of SARS-CoV-2 on hemoglobin kinetics and/or detection on the surface of the SARS-CoV-2 virion highly glycosylated S-proteins by high performance liquid chromatography determinations. Upon detection HbA1c > 6.0% in patients with COVID-19 in the active phase of the disease without concomitant hyperglycemia re-determine the level of HbA1c after recovery is recommended.

10 August 2020 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
ZKZ. A. Kalmykova
Z. A. Kalmykova
IKI. V. Kononenko
I. V. Kononenko
ISIgor Sklyanik
Igor Sklyanik
MSMarina Shestakova
Marina Shestakova
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
САСкляник Игорь Александрович
Скляник Игорь Александрович
Progressive decrease in the weight and functional reserve of -cells is one of the main pathogenetic mechanisms of development of type 2 diabetes mellitus (DM2). The rate of progression of these processes is strictly individual, which largely determines the course of DM2 and the effectiveness of the therapy. As a rule, apoptosis and necrosis are the main mechanisms of -cell damage and death in CD2. At the same time, recent studies allow us to consider the destruction and death of -cells as the outcome of other types of programmed cell death (PCG), the role of innate immunity in the Genesis of CD2 ISactively discussed. This article provides an overview of the data of domestic and foreign literature of recent years regarding the molecular, intracellular characteristics of different types of -cell PCG in CD2. The results of studies aimed at studying the possible factors and processes leading to their launch are presented.

15 October 2019 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
ZKZ A Kalmykova
Z A Kalmykova
IKI V Kononenko
I V Kononenko
AMA Yu Mayorov
A Yu Mayorov
In recent years there has been an active discussion about the relationship between diabetes mellitus (DM) and chronic liver diseases (CLD). On the one hand, patients with diabetes have an increased risk of developing CLD. On the other hand, patients with CLD very often identify abnormal glucose metabolism which ultimately leads to impaired glucose tolerance and the development of diabetes. This review outlines potential causal relationships between some CLD and DM. Common mechanisms that provoke metabolic and autoimmune disorders in the development of various nosologies of the CKD group, leading to steatosis, insulin resistance, impaired glucose tolerance and the development of diabetes are described. Certain features of the assessment of carbohydrate metabolism compensation in patients with hepatic dysfunction, anemia and protein metabolism disorders are described. Keywords: diabetes mellitus, chronic liver diseases, liver failure, cirrhosis, viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, insulin resistance, hypoglycemic drugs

16 September 2019 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
ZKZilya A. Kalmykova
Zilya A. Kalmykova
SVSvetlana Y. Vorotnikova
Svetlana Y. Vorotnikova
NFNatalia S. Fedorova
Natalia S. Fedorova
LDLarisa K Dzeranova
Larisa K Dzeranova
EPEKATERINA PIGAROVA
EKATERINA PIGAROVA
Alexander V. VorontsovAlexander V. Vorontsov
Alexander V. Vorontsov
Hyperprolactinemia (HP) is one of the most common neuroendocrine disorders. In 60% of cases, pathological HP is caused by pituitary prolactin-secreting adenoma. Therapy with agonists of dopamine type 2 receptors (D2 receptor agonists) is a method of choice for the treatment of pathological HP which allows to achieve prolactin normalization and reduction of pituitary adenoma in most cases. However, 15-20% of patients are resistant to D2 receptor agonists, and the question of overcoming this resistance is highly relevant. Different approaches are considered to solve this problem, one - is to increase the dose of D2 receptor agonists up to the maximally tolerated. In this article, we present a clinical observation of a patient with a partial resistance to D2 receptor agonists who demonstrated a good response to treatment with high doses of cabergoline.

12 February 2021 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
MSMarina Shestakova
Marina Shestakova
IKI. V. Kononenko
I. V. Kononenko
ZKZ. A. Kalmykova
Z. A. Kalmykova
AZAnna Zheleznyakova
Anna Zheleznyakova
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
Повышенный уровень гликированного гемоглобина (HbA 1c ) у больных с COVID-19 является маркером тяжести течения инфекции, но не индикатором предшествующего сахарного диабета